カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のMET阻害剤市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global MET Inhibitor Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO20808）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO20808
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：100
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のMET阻害剤市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

MET阻害剤市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のMET阻害剤の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

MET阻害剤市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGF拮抗薬抗体、クリングル変異拮抗薬　

用途別セグメントは次のように区分されます。
・病院調剤薬局、小売調剤薬局、その他

世界のMET阻害剤市場の主要な市場プレーヤーは以下のとおりです。
・Abbott Laboratories、Johnson and Johnson、Novartis International AG、Eli Lilly and Company、Pfizer Inc., Merck & Co.、Takeda Pharmaceutical Company、GlaxosmithKline plc、Amgen Inc.、Bristol Myers Squibb、Daiichi Sankyo Company, Limited

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、MET阻害剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なMET阻害剤メーカーの企業概要、2019年～2022年までのMET阻害剤の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なMET阻害剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別MET阻害剤の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのMET阻害剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのMET阻害剤市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびMET阻害剤の産業チェーンを掲載しています。
・第13、14、15章では、MET阻害剤の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- MET阻害剤の概要
- 種類別分析（2017年vs2021年vs2028年）：C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGF拮抗薬抗体、クリングル変異拮抗薬　
- 用途別分析（2017年vs2021年vs2028年）：病院調剤薬局、小売調剤薬局、その他
- 世界のMET阻害剤市場規模・予測
- 世界のMET阻害剤生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Abbott Laboratories、Johnson and Johnson、Novartis International AG、Eli Lilly and Company、Pfizer Inc., Merck & Co.、Takeda Pharmaceutical Company、GlaxosmithKline plc、Amgen Inc.、Bristol Myers Squibb、Daiichi Sankyo Company, Limited
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：C-Met生物学的阻害剤、低分子C-Met阻害剤、C-Metアンタゴニスト抗体、HGF拮抗薬抗体、クリングル変異拮抗薬　
・用途別分析2017年-2028年：病院調剤薬局、小売調剤薬局、その他
・MET阻害剤の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・MET阻害剤のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・MET阻害剤のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・MET阻害剤の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・MET阻害剤の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The MET Inhibitor Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global MET Inhibitor Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital Pharmacies accounting for % of the MET Inhibitor Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While C-Met Biological Inhibitors segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of MET Inhibitor Drugs include Abbott Laboratories, Johnson and Johnson, Novartis International AG, Eli Lilly and Company, and Pfizer Inc., Merck & Co., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
MET Inhibitor Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
C-Met Biological Inhibitors
Small Molecule C-Met Inhibitors
C-Met Antagonist Antibodies
HGF Antagonist Antibodies
Kringle Variant Antagonists
Market segment by Application can be divided into
Hospital Pharmacies
Retail Pharmacies
Others
The key market players for global MET Inhibitor Drugs market are listed below:
Abbott Laboratories
Johnson and Johnson
Novartis International AG
Eli Lilly and Company
Pfizer Inc., Merck & Co.
Takeda Pharmaceutical Company
GlaxosmithKline plc
Amgen Inc.
Bristol Myers Squibb
Daiichi Sankyo Company, Limited
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe MET Inhibitor Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of MET Inhibitor Drugs, with price, sales, revenue and global market share of MET Inhibitor Drugs from 2019 to 2022.
Chapter 3, the MET Inhibitor Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the MET Inhibitor Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and MET Inhibitor Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of MET Inhibitor Drugs.
Chapter 13, 14, and 15, to describe MET Inhibitor Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 MET Inhibitor Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global MET Inhibitor Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 C-Met Biological Inhibitors
1.2.3 Small Molecule C-Met Inhibitors
1.2.4 C-Met Antagonist Antibodies
1.2.5 HGF Antagonist Antibodies
1.2.6 Kringle Variant Antagonists
1.3 Market Analysis by Application
1.3.1 Overview: Global MET Inhibitor Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Others
1.4 Global MET Inhibitor Drugs Market Size & Forecast
1.4.1 Global MET Inhibitor Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global MET Inhibitor Drugs Sales in Volume (2017-2028)
1.4.3 Global MET Inhibitor Drugs Price (2017-2028)
1.5 Global MET Inhibitor Drugs Production Capacity Analysis
1.5.1 Global MET Inhibitor Drugs Total Production Capacity (2017-2028)
1.5.2 Global MET Inhibitor Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 MET Inhibitor Drugs Market Drivers
1.6.2 MET Inhibitor Drugs Market Restraints
1.6.3 MET Inhibitor Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories MET Inhibitor Drugs Product and Services
2.1.4 Abbott Laboratories MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Johnson and Johnson
2.2.1 Johnson and Johnson Details
2.2.2 Johnson and Johnson Major Business
2.2.3 Johnson and Johnson MET Inhibitor Drugs Product and Services
2.2.4 Johnson and Johnson MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Novartis International AG
2.3.1 Novartis International AG Details
2.3.2 Novartis International AG Major Business
2.3.3 Novartis International AG MET Inhibitor Drugs Product and Services
2.3.4 Novartis International AG MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Eli Lilly and Company
2.4.1 Eli Lilly and Company Details
2.4.2 Eli Lilly and Company Major Business
2.4.3 Eli Lilly and Company MET Inhibitor Drugs Product and Services
2.4.4 Eli Lilly and Company MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Pfizer Inc., Merck & Co.
2.5.1 Pfizer Inc., Merck & Co. Details
2.5.2 Pfizer Inc., Merck & Co. Major Business
2.5.3 Pfizer Inc., Merck & Co. MET Inhibitor Drugs Product and Services
2.5.4 Pfizer Inc., Merck & Co. MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Takeda Pharmaceutical Company
2.6.1 Takeda Pharmaceutical Company Details
2.6.2 Takeda Pharmaceutical Company Major Business
2.6.3 Takeda Pharmaceutical Company MET Inhibitor Drugs Product and Services
2.6.4 Takeda Pharmaceutical Company MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 GlaxosmithKline plc
2.7.1 GlaxosmithKline plc Details
2.7.2 GlaxosmithKline plc Major Business
2.7.3 GlaxosmithKline plc MET Inhibitor Drugs Product and Services
2.7.4 GlaxosmithKline plc MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Amgen Inc.
2.8.1 Amgen Inc. Details
2.8.2 Amgen Inc. Major Business
2.8.3 Amgen Inc. MET Inhibitor Drugs Product and Services
2.8.4 Amgen Inc. MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Bristol Myers Squibb
2.9.1 Bristol Myers Squibb Details
2.9.2 Bristol Myers Squibb Major Business
2.9.3 Bristol Myers Squibb MET Inhibitor Drugs Product and Services
2.9.4 Bristol Myers Squibb MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Daiichi Sankyo Company, Limited
2.10.1 Daiichi Sankyo Company, Limited Details
2.10.2 Daiichi Sankyo Company, Limited Major Business
2.10.3 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product and Services
2.10.4 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 MET Inhibitor Drugs Breakdown Data by Manufacturer
3.1 Global MET Inhibitor Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global MET Inhibitor Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in MET Inhibitor Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 MET Inhibitor Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 MET Inhibitor Drugs Manufacturer Market Share in 2021
3.5 Global MET Inhibitor Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and MET Inhibitor Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global MET Inhibitor Drugs Market Size by Region
4.1.1 Global MET Inhibitor Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global MET Inhibitor Drugs Revenue by Region (2017-2028)
4.2 North America MET Inhibitor Drugs Revenue (2017-2028)
4.3 Europe MET Inhibitor Drugs Revenue (2017-2028)
4.4 Asia-Pacific MET Inhibitor Drugs Revenue (2017-2028)
4.5 South America MET Inhibitor Drugs Revenue (2017-2028)
4.6 Middle East and Africa MET Inhibitor Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global MET Inhibitor Drugs Sales in Volume by Type (2017-2028)
5.2 Global MET Inhibitor Drugs Revenue by Type (2017-2028)
5.3 Global MET Inhibitor Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global MET Inhibitor Drugs Sales in Volume by Application (2017-2028)
6.2 Global MET Inhibitor Drugs Revenue by Application (2017-2028)
6.3 Global MET Inhibitor Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America MET Inhibitor Drugs Sales by Type (2017-2028)
7.2 North America MET Inhibitor Drugs Sales by Application (2017-2028)
7.3 North America MET Inhibitor Drugs Market Size by Country
7.3.1 North America MET Inhibitor Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America MET Inhibitor Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe MET Inhibitor Drugs Sales by Type (2017-2028)
8.2 Europe MET Inhibitor Drugs Sales by Application (2017-2028)
8.3 Europe MET Inhibitor Drugs Market Size by Country
8.3.1 Europe MET Inhibitor Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe MET Inhibitor Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific MET Inhibitor Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific MET Inhibitor Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific MET Inhibitor Drugs Market Size by Region
9.3.1 Asia-Pacific MET Inhibitor Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific MET Inhibitor Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America MET Inhibitor Drugs Sales by Type (2017-2028)
10.2 South America MET Inhibitor Drugs Sales by Application (2017-2028)
10.3 South America MET Inhibitor Drugs Market Size by Country
10.3.1 South America MET Inhibitor Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America MET Inhibitor Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa MET Inhibitor Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa MET Inhibitor Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa MET Inhibitor Drugs Market Size by Country
11.3.1 Middle East & Africa MET Inhibitor Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa MET Inhibitor Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of MET Inhibitor Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of MET Inhibitor Drugs
12.3 MET Inhibitor Drugs Production Process
12.4 MET Inhibitor Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 MET Inhibitor Drugs Typical Distributors
13.3 MET Inhibitor Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global MET Inhibitor Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global MET Inhibitor Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 4. Abbott Laboratories Major Business
Table 5. Abbott Laboratories MET Inhibitor Drugs Product and Services
Table 6. Abbott Laboratories MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Johnson and Johnson Basic Information, Manufacturing Base and Competitors
Table 8. Johnson and Johnson Major Business
Table 9. Johnson and Johnson MET Inhibitor Drugs Product and Services
Table 10. Johnson and Johnson MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Novartis International AG Basic Information, Manufacturing Base and Competitors
Table 12. Novartis International AG Major Business
Table 13. Novartis International AG MET Inhibitor Drugs Product and Services
Table 14. Novartis International AG MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 16. Eli Lilly and Company Major Business
Table 17. Eli Lilly and Company MET Inhibitor Drugs Product and Services
Table 18. Eli Lilly and Company MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Pfizer Inc., Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Inc., Merck & Co. Major Business
Table 21. Pfizer Inc., Merck & Co. MET Inhibitor Drugs Product and Services
Table 22. Pfizer Inc., Merck & Co. MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Takeda Pharmaceutical Company Basic Information, Manufacturing Base and Competitors
Table 24. Takeda Pharmaceutical Company Major Business
Table 25. Takeda Pharmaceutical Company MET Inhibitor Drugs Product and Services
Table 26. Takeda Pharmaceutical Company MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. GlaxosmithKline plc Basic Information, Manufacturing Base and Competitors
Table 28. GlaxosmithKline plc Major Business
Table 29. GlaxosmithKline plc MET Inhibitor Drugs Product and Services
Table 30. GlaxosmithKline plc MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 32. Amgen Inc. Major Business
Table 33. Amgen Inc. MET Inhibitor Drugs Product and Services
Table 34. Amgen Inc. MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 36. Bristol Myers Squibb Major Business
Table 37. Bristol Myers Squibb MET Inhibitor Drugs Product and Services
Table 38. Bristol Myers Squibb MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Daiichi Sankyo Company, Limited Basic Information, Manufacturing Base and Competitors
Table 40. Daiichi Sankyo Company, Limited Major Business
Table 41. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product and Services
Table 42. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global MET Inhibitor Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 44. Global MET Inhibitor Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in MET Inhibitor Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global MET Inhibitor Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and MET Inhibitor Drugs Production Site of Key Manufacturer
Table 48. MET Inhibitor Drugs New Entrant and Capacity Expansion Plans
Table 49. MET Inhibitor Drugs Mergers & Acquisitions in the Past Five Years
Table 50. Global MET Inhibitor Drugs Sales by Region (2017-2022) & (K Units)
Table 51. Global MET Inhibitor Drugs Sales by Region (2023-2028) & (K Units)
Table 52. Global MET Inhibitor Drugs Revenue by Region (2017-2022) & (USD Million)
Table 53. Global MET Inhibitor Drugs Revenue by Region (2023-2028) & (USD Million)
Table 54. Global MET Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 55. Global MET Inhibitor Drugs Sales by Type (2023-2028) & (K Units)
Table 56. Global MET Inhibitor Drugs Revenue by Type (2017-2022) & (USD Million)
Table 57. Global MET Inhibitor Drugs Revenue by Type (2023-2028) & (USD Million)
Table 58. Global MET Inhibitor Drugs Price by Type (2017-2022) & (US$/Unit)
Table 59. Global MET Inhibitor Drugs Price by Type (2023-2028) & (US$/Unit)
Table 60. Global MET Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 61. Global MET Inhibitor Drugs Sales by Application (2023-2028) & (K Units)
Table 62. Global MET Inhibitor Drugs Revenue by Application (2017-2022) & (USD Million)
Table 63. Global MET Inhibitor Drugs Revenue by Application (2023-2028) & (USD Million)
Table 64. Global MET Inhibitor Drugs Price by Application (2017-2022) & (US$/Unit)
Table 65. Global MET Inhibitor Drugs Price by Application (2023-2028) & (US$/Unit)
Table 66. North America MET Inhibitor Drugs Sales by Country (2017-2022) & (K Units)
Table 67. North America MET Inhibitor Drugs Sales by Country (2023-2028) & (K Units)
Table 68. North America MET Inhibitor Drugs Revenue by Country (2017-2022) & (USD Million)
Table 69. North America MET Inhibitor Drugs Revenue by Country (2023-2028) & (USD Million)
Table 70. North America MET Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 71. North America MET Inhibitor Drugs Sales by Type (2023-2028) & (K Units)
Table 72. North America MET Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 73. North America MET Inhibitor Drugs Sales by Application (2023-2028) & (K Units)
Table 74. Europe MET Inhibitor Drugs Sales by Country (2017-2022) & (K Units)
Table 75. Europe MET Inhibitor Drugs Sales by Country (2023-2028) & (K Units)
Table 76. Europe MET Inhibitor Drugs Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe MET Inhibitor Drugs Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe MET Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 79. Europe MET Inhibitor Drugs Sales by Type (2023-2028) & (K Units)
Table 80. Europe MET Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 81. Europe MET Inhibitor Drugs Sales by Application (2023-2028) & (K Units)
Table 82. Asia-Pacific MET Inhibitor Drugs Sales by Region (2017-2022) & (K Units)
Table 83. Asia-Pacific MET Inhibitor Drugs Sales by Region (2023-2028) & (K Units)
Table 84. Asia-Pacific MET Inhibitor Drugs Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific MET Inhibitor Drugs Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific MET Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 87. Asia-Pacific MET Inhibitor Drugs Sales by Type (2023-2028) & (K Units)
Table 88. Asia-Pacific MET Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 89. Asia-Pacific MET Inhibitor Drugs Sales by Application (2023-2028) & (K Units)
Table 90. South America MET Inhibitor Drugs Sales by Country (2017-2022) & (K Units)
Table 91. South America MET Inhibitor Drugs Sales by Country (2023-2028) & (K Units)
Table 92. South America MET Inhibitor Drugs Revenue by Country (2017-2022) & (USD Million)
Table 93. South America MET Inhibitor Drugs Revenue by Country (2023-2028) & (USD Million)
Table 94. South America MET Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 95. South America MET Inhibitor Drugs Sales by Type (2023-2028) & (K Units)
Table 96. South America MET Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 97. South America MET Inhibitor Drugs Sales by Application (2023-2028) & (K Units)
Table 98. Middle East & Africa MET Inhibitor Drugs Sales by Region (2017-2022) & (K Units)
Table 99. Middle East & Africa MET Inhibitor Drugs Sales by Region (2023-2028) & (K Units)
Table 100. Middle East & Africa MET Inhibitor Drugs Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa MET Inhibitor Drugs Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa MET Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 103. Middle East & Africa MET Inhibitor Drugs Sales by Type (2023-2028) & (K Units)
Table 104. Middle East & Africa MET Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 105. Middle East & Africa MET Inhibitor Drugs Sales by Application (2023-2028) & (K Units)
Table 106. MET Inhibitor Drugs Raw Material
Table 107. Key Manufacturers of MET Inhibitor Drugs Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. MET Inhibitor Drugs Typical Distributors
Table 111. MET Inhibitor Drugs Typical Customers
List of Figures
Figure 1. MET Inhibitor Drugs Picture
Figure 2. Global MET Inhibitor Drugs Revenue Market Share by Type in 2021
Figure 3. C-Met Biological Inhibitors
Figure 4. Small Molecule C-Met Inhibitors
Figure 5. C-Met Antagonist Antibodies
Figure 6. HGF Antagonist Antibodies
Figure 7. Kringle Variant Antagonists
Figure 8. Global MET Inhibitor Drugs Revenue Market Share by Application in 2021
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Others
Figure 12. Global MET Inhibitor Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 13. Global MET Inhibitor Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global MET Inhibitor Drugs Sales (2017-2028) & (K Units)
Figure 15. Global MET Inhibitor Drugs Price (2017-2028) & (US$/Unit)
Figure 16. Global MET Inhibitor Drugs Production Capacity (2017-2028) & (K Units)
Figure 17. Global MET Inhibitor Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. MET Inhibitor Drugs Market Drivers
Figure 19. MET Inhibitor Drugs Market Restraints
Figure 20. MET Inhibitor Drugs Market Trends
Figure 21. Global MET Inhibitor Drugs Sales Market Share by Manufacturer in 2021
Figure 22. Global MET Inhibitor Drugs Revenue Market Share by Manufacturer in 2021
Figure 23. MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 MET Inhibitor Drugs Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 MET Inhibitor Drugs Manufacturer (Revenue) Market Share in 2021
Figure 26. Global MET Inhibitor Drugs Sales Market Share by Region (2017-2028)
Figure 27. Global MET Inhibitor Drugs Revenue Market Share by Region (2017-2028)
Figure 28. North America MET Inhibitor Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Europe MET Inhibitor Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific MET Inhibitor Drugs Revenue (2017-2028) & (USD Million)
Figure 31. South America MET Inhibitor Drugs Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa MET Inhibitor Drugs Revenue (2017-2028) & (USD Million)
Figure 33. Global MET Inhibitor Drugs Sales Market Share by Type (2017-2028)
Figure 34. Global MET Inhibitor Drugs Revenue Market Share by Type (2017-2028)
Figure 35. Global MET Inhibitor Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 36. Global MET Inhibitor Drugs Sales Market Share by Application (2017-2028)
Figure 37. Global MET Inhibitor Drugs Revenue Market Share by Application (2017-2028)
Figure 38. Global MET Inhibitor Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 39. North America MET Inhibitor Drugs Sales Market Share by Type (2017-2028)
Figure 40. North America MET Inhibitor Drugs Sales Market Share by Application (2017-2028)
Figure 41. North America MET Inhibitor Drugs Sales Market Share by Country (2017-2028)
Figure 42. North America MET Inhibitor Drugs Revenue Market Share by Country (2017-2028)
Figure 43. United States MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe MET Inhibitor Drugs Sales Market Share by Type (2017-2028)
Figure 47. Europe MET Inhibitor Drugs Sales Market Share by Application (2017-2028)
Figure 48. Europe MET Inhibitor Drugs Sales Market Share by Country (2017-2028)
Figure 49. Europe MET Inhibitor Drugs Revenue Market Share by Country (2017-2028)
Figure 50. Germany MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific MET Inhibitor Drugs Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific MET Inhibitor Drugs Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific MET Inhibitor Drugs Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific MET Inhibitor Drugs Revenue Market Share by Region (2017-2028)
Figure 59. China MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America MET Inhibitor Drugs Sales Market Share by Type (2017-2028)
Figure 66. South America MET Inhibitor Drugs Sales Market Share by Application (2017-2028)
Figure 67. South America MET Inhibitor Drugs Sales Market Share by Country (2017-2028)
Figure 68. South America MET Inhibitor Drugs Revenue Market Share by Country (2017-2028)
Figure 69. Brazil MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa MET Inhibitor Drugs Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa MET Inhibitor Drugs Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa MET Inhibitor Drugs Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa MET Inhibitor Drugs Revenue Market Share by Region (2017-2028)
Figure 75. Turkey MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa MET Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of MET Inhibitor Drugs in 2021
Figure 80. Manufacturing Process Analysis of MET Inhibitor Drugs
Figure 81. MET Inhibitor Drugs Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のCDK4及び6阻害医薬品市場2022年：市場規模予測（～2028年）
  • 世界のプラスミノーゲンアクチベーターインヒビター1市場2022年：市場規模予測（～2028年）
  • 世界のアルファ-1 プロテイナーゼ阻害剤市場2022年：市場規模予測（～2028年）
  • 経口用JAK1阻害剤のグローバル市場展望 2023年-2029年：ブランド、バイオシミラー
  • 世界の抗レトロウイルスプロテアーゼ阻害剤市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO20808 )"世界のMET阻害剤市場2022年：市場規模予測（～2028年）" (英文：Global MET Inhibitor Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。